Michael Emig

5.5k total citations · 2 hit papers
46 papers, 4.0k citations indexed

About

Michael Emig is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Michael Emig has authored 46 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 13 papers in Surgery. Recurrent topics in Michael Emig's work include Gastric Cancer Management and Outcomes (19 papers), Colorectal Cancer Treatments and Studies (13 papers) and Chronic Myeloid Leukemia Treatments (10 papers). Michael Emig is often cited by papers focused on Gastric Cancer Management and Outcomes (19 papers), Colorectal Cancer Treatments and Studies (13 papers) and Chronic Myeloid Leukemia Treatments (10 papers). Michael Emig collaborates with scholars based in Germany, United States and United Kingdom. Michael Emig's co-authors include Eric Van Cutsem, Kei Muro, G. Bodoky, Atsushi Ohtsu, H. Wilke, Kumari Chandrawansa, Yasuhiro Shimada, David Cunningham, Shuichi Hironaka and Naotoshi Sugimoto and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Michael Emig

43 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

2014 1.7k citations H. Wilke, Kei Muro et al. The Lancet Oncology profile →
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

2009 1.0k citations Robert Pirker, Jose R. Pereira et al. The Lancet profile →

Peers

Countries citing papers authored by Michael Emig

Since Specialization

Citations

This map shows the geographic impact of Michael Emig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Emig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Emig more than expected).

Fields of papers citing papers by Michael Emig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Emig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Emig. The network helps show where Michael Emig may publish in the future.

Co-authorship network of co-authors of Michael Emig

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Emig. A scholar is included among the top collaborators of Michael Emig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Emig. Michael Emig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bispecific innate cell engager (ICE) AFM24 in combination with atezolizumab in patients with advanced/metastatic EGFR -expressing non-small cell lung cancer (NSCLC) without driver mutations: Initial results from a phase 2a study. 2025 ·Journal of Clinical Oncology ·Hye Ryun Kim, (unknown), Juanita Lopez, Anthony B. El-Khoueiry, Omar Saavedra, Jacob Thomas, Wojciech Rogowski, Valentina Boni, Cezary Szczylik, Andrés Cervantes, Iwona Ługowska, Rodryg Ramlau, Eric S. Christenson, Byoung Yong Shim, Marina Chiara Garassino, Ulrike Gärtner, Daniel Schütz, (unknown), Michael Emig, Daniela Morales-Espinosa	0
2	Preliminary results from the phase 2 study of AFM24 in combination with atezolizumab in patients with EGFR wild-type (EGFR-WT) non-small cell lung cancer (NSCLC). 2024 ·Journal of Clinical Oncology ·Hye Ryun Kim, Omar Saavedra, Andrés Cervantes, Iwona Ługowska, (unknown), Anthony B. El-Khoueiry, Jacob Thomas, Wojciech Rogowski, Juanita Lopez, Byoung Yong Shim, Eric S. Christenson, Valentina Boni, Marina Chiara Garassino, Ramón Yarza, (unknown), (unknown), (unknown), (unknown), Michael Emig, (unknown)	9
3	A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas 2024 ·Clinical Cancer Research ·Won Seog Kim, Jake Shortt, Pier Luigi Zinzani, (unknown), Dejan Radeski, Vincent Ribrag, Eva Domingo‐Doménech, Ahmed Sawas, (unknown), Michael Emig, (unknown), (unknown), Paulien Ravenstijn, Sheena Pinto, (unknown), (unknown), (unknown), Steven M. Horwitz	7
4	Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study 2024 ·Blood ·Joseph Maakaron, Dipenkumar Modi, Matthew Mei, Tatyana Feldman, Gunjan L. Shah, Amitkumar Mehta, Craig S. Sauter, Rashmi Khanal, Stefan K. Barta, Michael Emig, Lydia Wunderle, (unknown), (unknown), (unknown), Thorsten Graef, Heather K. Raymon, Alison J. Moskowitz	2
5	Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer 2020 ·The Oncologist ·Stefano Cascinu, G. Bodoky, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, Gunnar Folprecht, Sumitra Ananda, Gustavo Girotto, Zev A. Wainberg, (unknown), Jaffer A. Ajani, Ran Wei, Astra M. Liepa, Roberto Carlesi, Michael Emig, Atsushi Ohtsu	4
6	Efficacy and safety of ramucirumab (RAM) for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma across age subgroups in two global phase 3 trials. 2017 ·Journal of Clinical Oncology ·Kei Muro, Y. Choi, G. Bodoky, Chanchal Goswami, Yee Chao, Lucas Vieira dos Santos, Yasuhiro Shimada, (unknown), Eric Van Cutsem, Josep Tabernero, John Zalcberg, Ian Chau, Rebecca Cheng, Yanzhi Hsu, Michael Emig, Mauro Orlando, H. Wilke, Charles S. Fuchs	3
7	Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma 2016 ·Annals of Oncology ·Salah‐Eddin Al‐Batran, Eric Van Cutsem, Sang Cheul Oh, G. Bodoky, Yoshifumi Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, T.-Y. Kim, David Cunningham, P. Rougier, Kei Muro, Astra M. Liepa, Kumari Chandrawansa, Michael Emig, Atsushi Ohtsu, H. Wilke	55
8	A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117). 2016 ·Journal of Clinical Oncology ·Charles S. Fuchs, Josep Tabernero, Salah‐Eddin Al‐Batran, Ian Chau, David H. Ilson, Eric Van Cutsem, Kohei Shitara, David Ferry, Michael Emig, Veerle Vanvoorden, Yanzhi Hsu, Yihuan Xu, Andreas Sashegyi, Mayukh Das, Manish A. Shah	8
9	Candidate biomarker analyses in gastric or gastro-esophageal junction carcinoma: REGARD trial of single-agent ramucirumab (RAM) vs. placebo (PL). 2015 ·Journal of Clinical Oncology ·Charles S. Fuchs, Josep Tabernero, Jiří Tomášek, Ian Chau, Bohuslav Melichar, Howard Safran, Mustapha Tehfé, (unknown), (unknown), Luís Alberto Schlittler, Anghel Adrian Udrea, William Campbell, Stephen Brincat, Michael Emig, Symantha Melemed, Rebecca R. Hozak, David Ferry, (unknown), Jaffer A. Ajani	6
10	Rainbow: Global, Phase 3, Randomized, Double-Blind Study of Ramucirumab Plus Paclitaxel vs Placebo Plus Paclitaxel Patients with Previously Treated Gastric or Gastroesophageal Junction Adenocarcinoma – Patient-Reported Outcomes and Performance Status 2014 ·Annals of Oncology ·S. Al-Batran, Eric Van Cutsem, (unknown), G. Bodoky, Yoshifumi Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae Yong Kim, David Cunningham, P. Rougier, Kei Muro, (unknown), (unknown), Michael Emig, Atsushi Ohtsu, H. Wilke	1
11	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial breakdown → 2014 ·The Lancet Oncology ·H. Wilke, Kei Muro, Eric Van Cutsem, (unknown), G. Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae‐You Kim, David Cunningham, Philippe Rougier, Yoshito Komatsu, Jaffer A. Ajani, Michael Emig, Roberto Carlesi, David Ferry, Kumari Chandrawansa, Jonathan D. Schwartz, Atsushi Ohtsu	1715
12	Cetuximab plus platinum-based chemotherapy as 1st-line treatment in patients with non-small cell lung cancer (NSCLC): a meta-analysis of randomized phase II/III trials 2009 ·Journal of Thoracic Oncology ·Nick Thatcher, Thomas J. Lynch, Charles Butts, Rafael Rosell, Frances A. Shepherd, Jean-Louis Pujol, Johan Vansteenkiste, Michael Emig, Jutta Groos, Robert Pirker	15
13	Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial breakdown → 2009 ·The Lancet ·Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Ihor Vynnychenko, Keunchil Park, Chih-Teng Yu, (unknown), (unknown), Emilio Bajetta, Kenneth J. O’Byrne, Filippo de Marinis, Wilfried Eberhardt, Thomas Goddemeier, Michael Emig, U. Gatzemeier	1046
14	Fractalkine-upregulated milk-fat globule EGF factor-8 protein in cultured rat microglia 2005 ·Journal of Neuroimmunology ·Fernando Leonardi‐Essmann, Michael Emig, Yoshihisa Kitamura, Rainer Spanagel, Peter J. Gebicke‐Haerter	57
15	Harmonization of BCR-ABL mRNA Quantification Using an Uniform Control Plasmid in 36 International Laboratories. 2005 ·Blood ·Martin Mueller, Philipp Erben, Giuseppe Saglio, Enrico Gottardi, Thomas Schenk, Thomas Ernst, (unknown), Michael Emig, Rüediger Hehlmann, Andreas Hochhaus	3
16	Impact of Chemoradiotherapy-Induced Anemia on Survival in Uniformly Staged Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus 2004 ·Oncology Research and Treatment ·Ralf‐Dieter Hofheinz, B. Raab, Sabine Mai, Frederik Wenz, Frank Willeke, Michael Emig, Dieter Buchheidt, Rüdiger Hehlmann, Andreas Hochhaus	6
17	Detection and quantification of residual disease in chronic myelogenous leukemia 2000 ·Leukemia ·Andreas Hochhaus, A Weißer, Paul La Rosée, Michael Emig, M. C. Muller, Susanne Saußele, Andreas Reiter, Christian Kühn, Ute Berger, R. Hehlmann, Nicholas C.P. Cross	74
18	Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCR 1999 ·Leukemia ·Michael Emig, Susanne Saußele, (unknown), A Weißer, Andreas Reiter, Andreas Willer, Ute Berger, Rüdiger Hehlmann, Nicholas C.P. Cross, Andreas Hochhaus	207
19	A comparative study of five nitro musk compounds for genotoxicity in the SOS chromotest and Salmonella mutagenicity 1996 ·Toxicology Letters ·Michael Emig, (unknown), Volker Mersch‐Sundermann	26
20	Nitro musks are cogenotoxicants by inducing toxifying enzymes in the rat 1996 ·Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis ·Volker Mersch‐Sundermann, Michael Emig, (unknown)	25

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact